<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013905</url>
  </required_header>
  <id_info>
    <org_study_id>PR200-103</org_study_id>
    <secondary_id>2021-000092-37</secondary_id>
    <nct_id>NCT05013905</nct_id>
  </id_info>
  <brief_title>A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease</brief_title>
  <acronym>APOLLO-CD</acronym>
  <official_title>A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prometheus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prometheus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of PRA023 in participants with&#xD;
      moderately to severely active Crohn's Disease.&#xD;
&#xD;
      After the completion of the 12-week induction period, all participants have the option to&#xD;
      continue in the open-label extension for another 38 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Week 12</time_frame>
    <description>Incidence of adverse events (AE), serious adverse events (SAE), AE leading to discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopic improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving induction of endoscopic improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction of clinical remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving clinical remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of endoscopic and clinical improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with endoscopic and clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker and clinical improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with biomarker and clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of C-reactive protein</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with normalization of C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of fecal calprotectin</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with normalization of fecal calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two component patient-reported outcome (PRO-2) remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants achieving PRO-2 remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple endoscopy score for Crohn's Disease (SES-CD)</measure>
    <time_frame>Week 12</time_frame>
    <description>Assessment of change in SES-CD</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endoscopic Improvement and clinical remission by companion diagnostic (CDx) status</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of CDx+ participants achieving primary and key secondary efficacy outcome measures</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>PRA023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants to receive PRA023 administered by intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRA023 IV</intervention_name>
    <description>PRA023 administered at timepoints as directed by the protocol</description>
    <arm_group_label>PRA023</arm_group_label>
    <other_name>PRA023 administered by IV Infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Companion diagnostic (CDx)</intervention_name>
    <description>CDx+ or CDx-</description>
    <arm_group_label>PRA023</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Crohn's disease&#xD;
&#xD;
          -  Moderately to severely active CD as defined by Crohn's disease activity index (CDAI)&#xD;
             score and centrally read endoscopy&#xD;
&#xD;
          -  Must have corticosteroid dependence or have had no response, insufficient response,&#xD;
             loss of response and/or intolerance to at least one of the following therapies:&#xD;
             corticosteroid, immunosuppressants, or an approved anti-tumor necrosis factor (TNF),&#xD;
             anti-integrin, or anti-interleukin (IL)12/23&#xD;
&#xD;
          -  Able to provide written informed consent and understand and comply with the&#xD;
             requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) and men with female partner of childbearing&#xD;
             potential who are unwilling to use two highly effective methods of contraception to&#xD;
             avoid pregnancy for the entire study period and up to 12 weeks after the last dose of&#xD;
             study drug&#xD;
&#xD;
          -  Diagnosis of ulcerative colitis (UC) or indeterminate colitis&#xD;
&#xD;
          -  CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic&#xD;
             and/or illeal involvement&#xD;
&#xD;
          -  Suspected or diagnosed intra-abdominal or perianal abscess at screening&#xD;
&#xD;
          -  Current stoma or need for colostomy or ileostomy&#xD;
&#xD;
          -  Previous small bowel resection with a combined resected length of &gt;100 cm or previous&#xD;
             colonic resection of &gt; 2 segments&#xD;
&#xD;
          -  Surgical bowel resection within 3 months before screening&#xD;
&#xD;
          -  Past or current evidence of definite low-grade or high-grade colonic dysplasia not&#xD;
             completely removed&#xD;
&#xD;
          -  Subjects in the opinion of the investigator are at an unacceptable risk for&#xD;
             participation in the study&#xD;
&#xD;
          -  Subjects who meet the protocol criteria for important laboratory exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prometheus Biosciences</last_name>
    <role>Study Director</role>
    <affiliation>Clinicaltrials Call Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prometheus Biosciences</last_name>
    <phone>+1-858-332-0362</phone>
    <email>Clinicaltrials@prometheusbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prometheus Biosciences Selected Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prometheus Biosciences Call Center</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APOLLO-CD</keyword>
  <keyword>APOLLO</keyword>
  <keyword>Crohn's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

